Literature DB >> 17200347

High human papillomavirus oncogene mRNA expression and not viral DNA load is associated with poor prognosis in cervical cancer patients.

Marjon A de Boer1, Ekaterina S Jordanova, Gemma G Kenter, Alexander A Peters, Willem E Corver, J Baptist Trimbos, Gert Jan Fleuren.   

Abstract

PURPOSE: Cervical cancer is now known to be caused by infection with an oncogenic type of the human papillomavirus (HPV). However, little is known about the continued role of HPV once cancer has been established. Here, we describe the quantitative relation between HPV DNA copy number and mRNA expression of the viral oncogenes (E6 and E7) and the prognostic value of both measures in cervical cancer patients. EXPERIMENTAL
DESIGN: We studied the number of viral DNA copies and the level of HPV E6/E7 mRNA expression in 75 HPV 16-positive or HPV 18-positive International Federation of Gynecology and Obstetrics stage Ib and IIa cervical cancer patients. Measurements were done with quantitative PCR. DNA copy number analysis was done on pure tumor cell samples enriched with flow sorting. mRNA expression data were compensated for the percentage of tumor cells included.
RESULTS: The number of viral DNA copies was not predictive of survival in cervical cancer patients. In contrast, high HPV E6/E7 mRNA expression was strongly related to an unfavorable prognosis (P = 0.006). In a multivariate Cox model for overall survival, including all known prognostic variables and stratified for HPV type, the level of E6/E7 mRNA expression was an independent prognostic indicator, second only to lymph node status. No correlation was observed between DNA copy number and the level of HPV E6/E7 mRNA expression, which reflects that not all DNA copies are equally transcriptionally active.
CONCLUSIONS: Cervical cancer patients with high HPV E6/E7 oncogene mRNA expression have a worse survival independently from established prognostic factors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17200347     DOI: 10.1158/1078-0432.CCR-06-1568

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  30 in total

1.  How does tobacco smoke contribute to cervical carcinogenesis?

Authors:  Philip E Castle
Journal:  J Virol       Date:  2008-06       Impact factor: 5.103

2.  Significant association between host transcriptome-derived HPV oncogene E6* influence score and carcinogenic pathways, tumor size, and survival in head and neck cancer.

Authors:  Tingting Qin; Lada A Koneva; Yidan Liu; Yanxiao Zhang; Anna E Arthur; Katie R Zarins; Thomas E Carey; Douglas Chepeha; Gregory T Wolf; Laura S Rozek; Maureen A Sartor
Journal:  Head Neck       Date:  2020-05-14       Impact factor: 3.147

3.  Evidence of association of human papillomavirus with prognosis worsening in glioblastoma multiforme.

Authors:  Michele Vidone; Federica Alessandrini; Gianluca Marucci; Anna Farnedi; Dario de Biase; Fulvio Ricceri; Claudia Calabrese; Ivana Kurelac; Anna Maria Porcelli; Monica Cricca; Giuseppe Gasparre
Journal:  Neuro Oncol       Date:  2013-11-26       Impact factor: 12.300

4.  Retrospective analysis of HPV 16/18-related disease burden using archival clinical samples.

Authors:  Naureen Ehsan Ilahi; Shoaib Naiyar Hashmi; Sobia Anwar; Sheeba Murad
Journal:  J Cancer Res Clin Oncol       Date:  2016-08-30       Impact factor: 4.553

5.  Human papillomavirus oncoproteins differentially modulate epithelial-mesenchymal transition in 5-FU-resistant cervical cancer cells.

Authors:  Kanchan Vishnoi; Sutapa Mahata; Abhishek Tyagi; Arvind Pandey; Gaurav Verma; Mohit Jadli; Tejveer Singh; Sukh Mahendra Singh; Alok C Bharti
Journal:  Tumour Biol       Date:  2016-07-24

6.  Human papillomavirus is a favourable prognostic factor in tonsillar cancer and its oncogenic role is supported by the expression of E6 and E7.

Authors:  David Lindquist; Mircea Romanitan; Lalle Hammarstedt; Anders Näsman; Hanna Dahlstrand; Johan Lindholm; Liselotte Onelöv; Torbjörn Ramqvist; Weimin Ye; Eva Munck-Wikland; Tina Dalianis
Journal:  Mol Oncol       Date:  2007-09-01       Impact factor: 6.603

7.  Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Authors:  Stefania Bellone; Karim El-Sahwi; Emiliano Cocco; Francesca Casagrande; Marilisa Cargnelutti; Michela Palmieri; Eliana Bignotti; Chiara Romani; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

8.  Viral load, gene expression and mapping of viral integration sites in HPV16-associated HNSCC cell lines.

Authors:  Nadine C Olthof; Christian U Huebbers; Jutta Kolligs; Mieke Henfling; Frans C S Ramaekers; Iris Cornet; Josefa A van Lent-Albrechts; Alexander P A Stegmann; Steffi Silling; Ulrike Wieland; Thomas E Carey; Heather M Walline; Susanne M Gollin; Thomas K Hoffmann; Johan de Winter; Bernd Kremer; Jens P Klussmann; Ernst-Jan M Speel
Journal:  Int J Cancer       Date:  2014-08-14       Impact factor: 7.396

9.  Genomic instability of the host cell induced by the human papillomavirus replication machinery.

Authors:  Meelis Kadaja; Alina Sumerina; Tatjana Verst; Mari Ojarand; Ene Ustav; Mart Ustav
Journal:  EMBO J       Date:  2007-03-29       Impact factor: 11.598

10.  Guidelines of the Italian Society for Virology on HPV testing and vaccination for cervical cancer prevention.

Authors:  Luisa Barzon; Colomba Giorgi; Franco M Buonaguro; Giorgio Palù
Journal:  Infect Agent Cancer       Date:  2008-12-16       Impact factor: 2.965

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.